Dyadic Logo Current.jpg
Dyadic Reports 2023 Full Year Results and Recent Company Progress
March 28, 2024 16:00 ET | Dyadic International, Inc.
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical...
Dyadic Logo Current.jpg
Dyadic to Attend Industry Events in April
March 27, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
January 02, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
June 21, 2023 08:33 ET | Dyadic International, Inc.
JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Dyadic Logo Current.jpg
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
January 24, 2023 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Pfizer and BioNTech
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
August 23, 2022 06:45 ET | BioNTech SE
Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children ages 6 months through 4 yearsThe vaccine efficacy remained...
Pfizer und BioNTech
Pfizer und BioNTech geben Update zur Wirksamkeit ihres COVID-19-Impfstoffs bei Kindern von 6 Monaten bis 4 Jahren
August 23, 2022 06:45 ET | BioNTech SE
Daten einer weiterführenden Analyse mit 34 Fällen, die mindestens sieben Tage nach Verabreichung der primären Impfserie bestehend aus drei Dosen auftraten, zeigen eine Impfstoffwirksamkeit von 73,2 %...
Dr. William Haseltine releases new book on Innate Immunity and Covid-19
March 16, 2022 13:37 ET | ACCESS Health International
New York, March 16, 2022 (GLOBE NEWSWIRE) -- In his latest book, bestselling author William A. Haseltine Ph.D. tells us that understanding our natural immunity to the SARS-CoV-2 virus is critical...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
March 15, 2022 18:00 ET | BioNTech SE
Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who...
Pfizer und BioNTech
Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren
January 25, 2022 06:45 ET | BioNTech SE
Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...